Evaluating Treatments for Suicidal Veterans With PTSD

NCT05974631 — Not applicable, Recruiting, 125 participants, VA Office of Research and Development

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Hybrid Effectiveness-Implementation Trial of Treatments for Veterans With PTSD at Elevated Acute Risk for Suicide

RegistryNCT05974631
StatusRecruiting
PhaseNot applicable
Study typeInterventional; randomized, parallel, masking: single, treatment
Enrollment125 (Estimated)
SponsorVA Office of Research and Development (Fed)
ConditionsSelf-directed Violence, Post-traumatic Stress Disorder (PTSD)
InterventionsDialectical Behavior Therapy, Dialectical Behavior Therapy Prolonged Exposure protocol, Prolonged Exposure therapy, Suicide risk management (Behavioral)
Datesstart 2024-07-08, primary completion 2027-04-30 (estimated), completion 2028-08-31 (estimated), first posted 2023-08-03, last updated 2026-07-16
Locations4 sites in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Self-directed Violence All trials for Post-traumatic Stress Disorder (PTSD) All trials of Dialectical Behavior Therapy All trials of Dialectical Behavior Therapy Prolonged Exposure protocol

-Summary

Posttraumatic Stress Disorder (PTSD) is a significant driver of suicide risk among Veterans, but there is a critical knowledge gap about how to treat PTSD among people at elevated risk for suicide. Although evidence-based treatments for PTSD reduce suicide risk, Veterans at high risk for suicidal behavior rarely receive these potentially life-saving treatments. Prior research suggests that a treatment that combines Dialectical Behavior Therapy (DBT) with the DBT Prolonged Exposure protocol (DBT PE) for PTSD improves both PTSD and suicide-related outcomes. This study will evaluate whether DBT + DBT PE improves these outcomes more than Prolonged Exposure plus suicide risk management, the gold standard VA care for this population. The proposed study will also examine factors that make it easier and harder to implement these treatments in VA settings. The results will help to inform treatment guidelines for this high-priority Veteran population.

Expand all sections  ·  Collapse all

+Detailed description

Background: Posttraumatic stress disorder (PTSD) is a significant risk factor for suicide among Veterans. Evidence-based psychotherapies (EBPs) for PTSD reduce suicide risk, but Veterans at elevated acute risk for suicide, such as those who have engaged in self-directed violence (SDV), rarely receive these treatments. This is largely due to the historical exclusion of high-risk individuals from PTSD treatment trials, which has resulted in a lack of evidence-based guidance about indicated treatments for this population. Without such guidance, clinicians are often reluctant to use EBPs for PTSD with suicidal individuals. A treatment that combines Dialectical Behavior Therapy (DBT), a suicide-focused EBP, with the DBT Prolonged Exposure (DBT PE) protocol for PTSD has been developed for this high-risk population and shows promise in reducing both SDV and PTSD while being feasible, acceptable, and safe to deliver. However, a large-scale randomized controlled trial (RCT) is needed. This study will compare the effectiveness of DBT + DBT PE to the current VHA gold standard of care for this population, Prolonged Exposure therapy augmented with suicide risk management (PE + SRM), while also examining the potential for implementation of both interventions in VHA.

Significance: There is a critical gap in knowledge about how to treat PTSD among individuals at high risk for suicidal behavior. As a result, VA/DoD Clinical Practice Guidelines do not specify indicated treatment strategies for this population. Experts have recommended two approaches to facilitate the safe and effective use of EBPs for PTSD with individuals at elevated acute suicide risk, including combining these treatments with suicide-focused EBPs or augmenting them with suicide risk management strategies. This project will help to fill this critical gap by rigorously evaluating these two approaches among Veterans with SDV. The results will provide important information to inform guidelines about indicated treatments for this high-risk population.

Innovativeness: This will be the first large-scale RCT to evaluate treatments for PTSD among Veterans who have engaged in SDV, an HSR\&D high priority group. The DBT + DBT PE intervention is the first treatment designed to address both SDV and PTSD, and results will indicate if this novel treatment improves outcomes compared to the current VHA gold standard of care. To facilitate more rapid implementation of these findings into clinical practice, implementation barriers and facilitators for both treatments will also be evaluated.

Specific Aims: This study will randomize 125 Veterans with PTSD, recent and repeated SDV, current suicidal ideation, and emotion dysregulation to DBT + DBT PE (intervention) or PE + SRM (control). Aim 1 will test the hypothesis that DBT + DBT PE will be superior to PE + SRM in improving clinical outcomes and engagement in trauma-focused treatment. Exploratory analyses will examine Veteran characteristics that may predict better engagement and outcomes in DBT + DBT PE versus PE + SRM. Aim 2 will examine barriers and facilitators to implementation of both treatments.

Methods: This is a multi-site hybrid type 1 effectiveness-implementation trial. Veterans will be treated in outpatient settings at four VA sites and assessed at 5 points over 16 months. A mixed-methods approach will be used to evaluate barriers and facilitators to implementation, including conducting interviews with 45 key stakeholders (Veterans, providers, and leadership).

Primary Outcomes/Endpoints: Primary outcomes will be reductions in SDV episodes at 16-month follow-up and reductions in PTSD severity at post-treatment.

Implementation/Next Steps: This project will provide much-needed information about how to safely and effectively treat PTSD among Veterans at elevated acute risk for suicide. If one or both treatments are found effective, Aim 2 will provide vital information about how to maximize future implementation success. Future implementation activities would be coordinated with the investigators' national operational partners.

+Arms and interventions

ArmTypeInterventionsDescription
DBT + DBT PEExperimentalBehavioral: Dialectical Behavior Therapy; Behavioral: Dialectical Behavior Therapy Prolonged Exposure protocolThis condition combines one year of standard Dialectical Behavior Therapy (DBT) with the DBT Prolonged Exposure (DBT PE) protocol for PTSD.
PE + SRMActive comparatorBehavioral: Prolonged Exposure therapy; Behavioral: Suicide risk managementThis condition provides up to 18 sessions of Prolonged Exposure therapy (PE) for PTSD augmented with suicide risk management (SRM).
  • Dialectical Behavior Therapy (Behavioral), also known as DBT: Standard Dialectical Behavior Therapy (DBT), including DBT individual therapy (1 hour/week), DBT group skills training (2 hours/week), between-session coaching (as needed during business hours), and therapist consultation team (1-1.5 hours/week).
  • Dialectical Behavior Therapy Prolonged Exposure protocol (Behavioral), also known as DBT PE: DBT PE is designed to be integrated into DBT to formally treat PTSD once patients meet standardized readiness criteria. The core procedures are in vivo and imaginal exposure with processing that are delivered in individual therapy sessions (1.5 hours/week).
  • Prolonged Exposure therapy (Behavioral), also known as PE: Standard PE is delivered in individual therapy sessions (1.5 hours/week) and uses the core procedures of in vivo and imaginal exposure with processing.
  • Suicide risk management (Behavioral), also known as SRM: Standard VA suicide risk management procedures, including comprehensive suicide risk assessment and safety planning.

+Outcome measures

Primary outcomes

  • Self-Injurious Thoughts and Behaviors Interview - Revised Short Form (SITBI-R-SF) [Baseline to 16 months]: Number of self-directed violence episodes
  • Clinician-Administered PTSD Scale for DSM-5 Revised (CAPS-5-R) [Baseline to 16 months]: Total Severity Score (range = 0 - 200, higher is worse)

Secondary outcomes

  • Columbia - Suicide Severity Rating Scale (C-SSRS), Suicide Ideation subscales [Baseline to 16 months]: Total Score (range = 0 - 5, higher is worse)
  • PROMIS Global Mental Health [Baseline to 16 months]: Total Score (range = 4 - 20, higher is better)
  • Difficulties in Emotion Regulation Scale-16 (DERS-16) [Baseline to 16 months]: Total Score (range = 16 - 80, higher is worse)
  • World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) [Baseline to 16 months]: General Disability Score (range = 12 - 60, higher is worse)
  • Self-Injurious Thoughts and Behaviors Interview Revised Short Form (SITBI-R-SF) [Baseline to 16 months]: Non-suicidal self-injury frequency and remission; Suicide attempt frequency and remission
  • Clinician-Administered PTSD Scale for DSM-5 Revised (CAPS-5-R) [Baseline to 16 months]: PTSD diagnostic status

Other outcomes

  • Treatment History Interview (THI) [Baseline to 16 months]: Non-VA psychotherapy, psychiatric crisis services, and psychotropic medications
  • VA Service Use Form [Baseline to 16 months]: VA mental health service use and psychotropic medications
  • Credibility Expectancy Questionnaire (CEQ) [Baseline to 16 months]: Total score (range = 1 - 7, higher is better)
  • Client Satisfaction Questionnaire (CSQ) [Post-treatment (4 months in PE + SRM, 12 months in DBT + DBT PE)]: Total score (range = 8 - 32, higher is better)
  • Dissociative Experiences Scale - Taxon (DES-T) [Baseline to 16 months]: Total score (range = 0 - 80, higher is worse)
  • Trauma-Related Shame Inventory (TRSI) [Baseline to 16 months]: Total score (range = 0 - 72, higher is worse)
  • Self-Compassion Scale (SCS) [Baseline to 16 months]: Total score (range = 1 - 5, higher is better)
  • Borderline Symptom List - Behavioral Supplement (BSL-BS) [Baseline to 16 months]: Total score (range = 0 - 44, higher is worse)
  • PTSD Checklist for DSM-5 (PCL-5) [Baseline to 16 months]: Total severity score (range = 0 - 80, higher is worse)
  • Post-Traumatic Cognitions Inventory-9 (PTCI-9) [Baseline to 16 months]: Total score (range = 9 to 63, higher is worse)
  • PROMIS Sadness [Baseline to 16 months]: Total score (range = 8 - 40, higher is worse)
  • PROMIS Fear-Affect [Baseline to 16 months]: Total score (range = 7 - 35, higher is worse)
  • PROMIS Anger-Affect [Baseline to 16 months]: Total score (range = 5 - 25, higher is worse)

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* PTSD
* Recent and repeated self-directed violence
* Current suicidal ideation
* Emotion dysregulation
* Veteran eligible for VHA mental health care at participating site
* Willing to participate in all study activities

Exclusion Criteria:

* Unable to maintain safety independently
* Currently engaged in and/or recent (past year) history of receiving a sufficient dose of DBT or PE
* Plan to move away or be unavailable for >4 weeks in the next 18 months
* Unable to sufficiently comprehend study procedures due to lack of English proficiency or moderate to severe cognitive impairment

+Locations (4)

FacilityCityCountryStatus
Minneapolis VA Health Care System, Minneapolis, MNMinneapolis, MinnesotaUnited StatesRecruiting
Durham VA Medical Center, Durham, NCDurham, North CarolinaUnited StatesRecruiting
South Texas Health Care System, San Antonio, TXSan Antonio, TexasUnited StatesRecruiting
VA Puget Sound Health Care System Seattle Division, Seattle, WASeattle, WashingtonUnited StatesRecruiting

+Publications

  • Results publication: Harned MS, Ready CB, Andrews Wiebusch LM, Landes SJ, Blalock DV, Waddell ZE, Carter JM, Hembree EA, Meis LA. Evaluating psychotherapies for veterans with PTSD at elevated acute risk of suicide: Protocol for a multi-site type 1 hybrid effectiveness-implementation trial. Contemp Clin Trials. 2026 Aug 15:108433. doi: 10.1016/j.cct.2026.108433. Online ahead of print. PMID 42603614

+Investigators

  • Melanie S Harned, PhD, Principal investigator, VA Puget Sound Health Care System Seattle Division, Seattle, WA